Advicenne is a specialty pharmaceutical company dedicated to patients suffering from rare and neglected diseases. The company has already started selling products but its flagship drug candidate, ADV7103, is currently pending European marketing authorization for distal renal tubular acidosis (dRTA), a condition characterized by an imbalance in the pH of the blood. At Advicenne, we are committed to developing and commercializing medications that are adapted to both children and adults – because pathbreaking treatments for rare diseases should be available to patients of all ages.